Avadel Pharmaceuticals plc AVDL · Stock Open Avadel Pharmaceuticals plc in new tab
Avadel Pharmaceuticals plc Analysis (AVDL)
Is Avadel Pharmaceuticals plc a good investment? Avadel Pharmaceuticals plc (AVDL) is currently trading at 21.64 USD.
Earnings Schedule: Avadel Pharmaceuticals plc is expected to release its next earnings report on May 5, 2026.
Investor FAQ
Does Avadel Pharmaceuticals plc pay a dividend?
No, it does not currently pay a dividend.
What asset class is Avadel Pharmaceuticals plc?
Avadel Pharmaceuticals plc is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be May 5, 2026.
Company Profile
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Community Discussion